Quantcast

Latest Tyrosine kinase Stories

2014-09-04 08:30:28

SAN DIEGO, Sept. 4, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression. "This study is designed to identify an optimal dose and...

2014-08-14 08:29:14

-- Anti-EphA3 Agents Inhibit Tumor Growth by Disrupting or Destroying the Tumor Microenvironment: Malignant Stem Cells, Stromal Cells, and New Tumor Vasculature -- SOUTH SAN FRANCISCO, Calif., Aug. 14, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and...

2014-08-05 08:33:13

Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug. 5, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today publication of a case study in which the company's comprehensive tumor profiling service, Caris Molecular Intelligence(TM), helped guide successful...

2014-07-29 08:31:52

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report second quarter operational results after closing of the NASDAQ Global Market on Tuesday, August 12, 2014. A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the...

2014-05-30 10:16:03

Ohio State University Wexner Medical Center A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL). The study was published in the New England Journal of Medicine and led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). It identifies gene mutations that...

2014-05-29 15:51:33

University of Chicago Medical Center Pinpointing cause of relapse could lead to better therapies A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of...

2014-05-28 08:30:57

SAN DIEGO, May 28, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ:AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Jefferies 2014 Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on June 2-5, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2014-05-15 08:31:37

ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss for the first quarter of 2014 of ($1.5 million), or ($0.05) per share, compared with a net loss of ($1.1 million), or ($0.05) per share,...

2014-05-01 08:35:41

SAN DIEGO, Calif., May 1, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Deutsche Bank 39(th) Annual Healthcare Conference to be held at the InterContinental Hotel in Boston, MA, May 7-8, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug...

2014-04-09 12:31:42

Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014. BGB324 is a first-in-class, highly selective small molecule inhibitor...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related